← Back to Search

Platelet-rich Plasma

PRP Injections for Shoulder Osteoarthritis

Phase 4
Recruiting
Research Sponsored by Hospital for Special Surgery, New York
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months post-injection
Awards & highlights
Drug Has Already Been Approved
Pivotal Trial

Summary

This trial will compare treatments for glenohumeral OA: physical activity, injections, medications, low-dose PRP, high-dose PRP and saline injections. Results will determine which is most effective.

Who is the study for?
This trial is for adults aged 18-100 with shoulder osteoarthritis who've had pain for at least 3 months despite trying physical therapy and other conservative treatments. Participants need an email or network access, an MRI of the affected joint, and a pain score of at least 5/10 due to the condition. They must have experienced temporary relief from a diagnostic joint injection. Those on NSAIDs can't join, nor can those involved in workers' comp claims, recent recipients of certain injections or treatments, or individuals with uncontrolled illnesses.
What is being tested?
The study tests single injections of two different doses of PRP (Platelet-Rich Plasma) against saline to see which is more effective for shoulder osteoarthritis. Previous studies used low-dose PRP; this one includes both low-dose (~3X concentration) and high-dose PRP to compare outcomes.
What are the potential side effects?
PRP may cause side effects such as pain at the injection site, tissue damage, infection risk increase due to needle insertion into the joint space, allergic reactions or increased inflammation within the treated area.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months post-injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months post-injection for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
American Shoulder and Elbow Surgeons (ASES) Shoulder Score
Secondary study objectives
Average numerical rating scale (NRS) pain score
Medication use
PROMIS Sleep Disturbance
+3 more

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Low-dose PRPExperimental Treatment1 Intervention
Patients will receive a single injection of 6 ml low-dose platelet-rich plasma (PRP) into the glenohumeral joint. Low-dose is defined as a platelet yield of 3X (i.e., 3-fold increase in platelets in PRP compared to whole blood).
Group II: High-dose PRPExperimental Treatment1 Intervention
Patients will receive a single injection of 6 ml high-dose platelet-rich plasma (PRP) into the glenohumeral joint. High-dose is defined as a platelet yield of 12X (i.e., 12-fold increase in platelets in PRP compared to whole blood).
Group III: Saline controlPlacebo Group1 Intervention
Patients will receive a single injection of 6 ml saline into the glenohumeral joint.

Find a Location

Who is running the clinical trial?

Hospital for Special Surgery, New YorkLead Sponsor
250 Previous Clinical Trials
61,201 Total Patients Enrolled

Media Library

High-dose PRP (Platelet-rich Plasma) Clinical Trial Eligibility Overview. Trial Name: NCT05675527 — Phase 4
Shoulder Osteoarthritis Research Study Groups: Low-dose PRP, High-dose PRP, Saline control
Shoulder Osteoarthritis Clinical Trial 2023: High-dose PRP Highlights & Side Effects. Trial Name: NCT05675527 — Phase 4
High-dose PRP (Platelet-rich Plasma) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05675527 — Phase 4
Shoulder Osteoarthritis Patient Testimony for trial: Trial Name: NCT05675527 — Phase 4
~40 spots leftby Sep 2025